I’ve been on this board long enough to see most posters
I’ve been on this board long enough to see most posters true investment strategy. Overwhelming amount of shorts and flippers are the ones posting since last night and into this morning. There have only been a handful of longs using common sense analysis of the data and comparing it against what FDA has stated criteria for EUA and comparing against the current. For the last year we have had to deal with shorts, bashers, flippers tell us that are drug does not work on anything and that were going no where but down. They also claimed in the past that any and every competing drug was going to get approved and would be better than CYDY Leronlimab. The results that we have been given tell the real story - #1 best therapeutic at reducing mortality in the sickest (critical) patients giving them best chance of survival. There is no other drug to compare out results to unless you want to use the Latest PR comparison of 2% we are 12x better. The next data endpoint we were given was 6 days reduced hospital stay vs the SOC. Keep in mind remsavier was given EUA even though they have some pretty nasty side effects by reducing hospital stay by 2 days. Third data endpoint shows a 166% better chance compared to SOC to be discharged alive from hospital at day 28. All of these are huge breakthroughs in which no other drug can show that they could do any of those 3 things never mind the same drug replicate all those positive results. EUA is imminent we already know the FDA and CYDY would like more critical patients enrolled and I believe this path forward is aimed at full approval. FDA has a plethora of data that shows an astounding benefit vs risk (little to NO SAE) taking this drug prob would results in 99.999% chance of better recovery than getting a SAE from taking it. I hope most of the longs and even new investors understand how valuable the shares they are currently holding will be there are already a ton 20+ million short shares out and with any big media we may get over this weekend could really send this stock gapping up in multiples. If media is lagged the shorts may win at getting stock yo briefly decline but media will pick up on it and CYDY will be getting more PR out new investors and stock price will go up with communications of sales to US, MHRA, Canada, Phillipines and Brazil. Brazil might be the new front runner to take as much of the supply as they can get ans give EUA. Looking forward to Monday I think we will get more positive news.
16
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
APTA 2026: The Launchpad for Intelligent Traffic Control Forget the days of manual traffic chaos—by the sounds of it, smart intersections are ready to rule the roads. Today's chatter at APTA 2026 in Chicago was a whirlwind of ideas, all centered around how ICP DAS and Towards Buddha Co., Ltd. plan to shake up traffic management globally with their iTLC Intelligent...
Continue Reading
Under the Radar, but Not for Long Ah, mergers—those grand gestures in corporate America that promise growth, synergy, and shareholder value. But not every deal is a head-turner; some fly under the radar until someone grabs the magnifying glass. And that's exactly what's happening with Main Street Financial Services Corp.'s (OTC: MSWV) proposed merger with First...
Continue Reading
Building Bridges Across Waters These aren't the afternoons of trading stocks, folks—this one dives into the depths of the ocean and the tumultuous waters between China and Malaysia. October 30 saw the China-Malaysia Youth Ocean Dialogue take place at the China Media Group Sanya Studio, bringing together some sharp minds from both nations, tackling something that goes...
Continue Reading
From the Shadows to the Spotlight Ever seen someone step up to the plate and knock it out of the park? That's what the United Breast Cancer Foundation (UBCF) is doing by plastering their mission right across Times Square. Talk about grabbing the bull by the horns, eh? With not one, but two billboards now gracing one of the globe's most iconic public spaces, they've...
Continue Reading
On The Ground: NABEP's Expanding Venezuelan Presence Think of oil production as a high-stakes poker game where each drill and rig is a well-placed bet. North American Blue Energy Partners (NABEP) is going all in on Venezuela, boosting their rig fleet and pushing production capacity to new heights. Set your sights on November when NABEP's in-country fleet will hit 41 rigs...
Continue Reading
A New Frontier in Document Parsing Just when you thought document parsing couldn't get any more advanced, ModelBest and OpenBMB come along with a game-changing release: the MiniCPM-OCR series. This duo of dynamite models, MiniCPM-OCR 1.0 and Jev, is all about taking the efficiency and performance expectations for open-source OCR models up a couple of notches. If you're an...
Continue Reading
Pivotal Point for Zhimeng's ALS Efforts Folks, get this—Zhimeng Biopharma's rolling out the big guns here with a significant step forward in their ALS treatment quest. This company just wrapped up patient enrollment for their next-gen ALS drug, CB03-154. We're talking about 255 patients now on board for a Phase 2/3 trial. The ground's shaking a bit because this...
Continue Reading
New Spin on an Old Favorite: Rice Noodles Forget about the same old wheat noodles clogging up the pantry. HanAll F&B is revamping the noodle game with a homegrown twist, setting sights on a future where Korean rice isn't just for steaming, soup, or sushi. This outfit from Taebaek, Gangwon, has got its hands deep in the rice flour, finessing a patent that aims to make...
Continue Reading
A New Era for Bass Fishing Payouts Who would have thought we'd see the day when bass fishing turned out to be as lucrative as a Wall Street handshake? But here we are, with Matt Robertson hauling in a whopping $1.25 million prize at World Bass Enterprises' first "The Champions" Tournament. We're not talking chump change here—this is the real deal in a sport often...
Continue Reading
Pushing Boundaries at CES 2027 Kicking into high gear, NIDS Co., Ltd. is eyeing the CES 2027 stage like it's their personal gold rush. Already a heavyweight in environmental sensors, the company is all set to seize fresh international opportunities and expand their B2B supply footprint worldwide. Already Turning Heads Founded back in 2000, NIDS ain't new to the sensor...
Continue Reading
